We are a clinical-stage microbiome therapeutics company aiming to restore and modulate patient-microbiome symbiosis to improve survival in cancer. To do so, we are developing a novel class of microbiome drug candidates: Microbiome Ecosystem Therapies (MET). MET are high-diversity, high-richness, indication-specific products aiming to leverage the full functional diversity of a microbiome ecosystem. Our MET drug development platform leverages gutPrint®, our proprietary AI-based computational biology and our proprietary cGMP manufacturing capacities to deliver innovative new drugs for the treatment of graft-vs-host-disease , the prevention of complications of HSCT for patients with liquid tumors and the improvement of response to immune checkpoint inhibitors in solid tumors. Our team combines expertise ranging from microbiology to data science to oncology and benefits from the commitment of world-leading scientists.
Building a leading microbiome company in oncology
We are a clinical-stage microbiome therapeutics company aiming to
improve survival in cancer.
Corporate profile
Press Releases

September 12, 2023: MaaT Pharma and Skyepharma Complete Construction of Europe’s Largest Manufacturing Facility for Microbiome Ecosystem Therapies

September 8, 2023: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital

September 7, 2023: MaaT Pharma Announces European Medicines Agency Granted MaaT033 Orphan Drug Designation Aiming to Improve Overall Survival in Patients Undergoing Hematopoietic Stem Cell transplantation
Media Coverage

September 19, 2023: Le Point – Traitement des cancers : le microbiote intestinal passe en phase industrielle (French only)

September 13, 2023: Endpoints News – MaaT Pharma and CDMO Skyepharma unveil bespoke, and potentially largest, microbiome facility in Europe

April 28, 2023: Microbiome Times – FDA Lifts Hold on Maat Pharma’s Phase 3 Investigational NDA for MaaT013
Posters

Benchmarking of shotgun metagenomics analysis results obtained with state-of-the-art optimized pipelines on simulated gut microbiome samples

Restoration of gut microbiota diversity with oral pooled fecal microbiotherapy in acute myeloid leukemia patients after intensive chemotherapy: the phase 1b CIMON trial

Pooled allogenic fecal microbiotherapy MaaT013 for the treatment of steroid-refractory gastrointestinal acute graft-versus-host disease: results from the phase IIa HERACLES study and expanded access program
